Levilimab

Phase 3Monoclonal antibody

BBiocad

Levilimab is one of 34 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Levilimab

BBiocad

Phase 3

1 2

Actos

Takeda

Preclinical

2 3

Celexa

AbbVie

Preclinical

1 4

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Rheumatoid Arthritis

NCT05800327

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

Active, not recruiting·BBiocad·Phase 3·NCT05800327·261 enrolled

COVID-191 trial

A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Completed·BBiocad·Phase 3·NCT04397562·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Levilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: BBiocad

Levilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Rheumatoid Arthritis1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News